BOSTON, Feb. 23 /PRNewswire-FirstCall/ -- PAREXEL International Corporation , a leading global biopharmaceutical services provider, today announced that it has expanded its capabilities through the opening of a new early phase unit in Port Elizabeth, South Africa. The Port Elizabeth unit has added more than 40 beds to PAREXEL’s global early phase capacity of over 580 beds, which is among the largest capacities worldwide. In addition to providing the capability to conduct a variety of studies in healthy volunteers, the core focus of the Port Elizabeth unit is on early phase studies in patients, from First in Man to Proof of Concept studies.
“Increasing the number of patients per site and reducing the overall number of sites in a study serves to decrease variability--improving study quality and reproducibility,” said Michelle Middle, MB ChB, Corporate Vice President and Worldwide Head of Early Phase, PAREXEL International. “The opening of our early phase unit in Port Elizabeth represents PAREXEL’s further commitment to offering rapid recruitment solutions to our clients. Port Elizabeth joins our other early phase units, which are integrated and harmonized to handle complex global studies involving healthy volunteers and patient populations.”
PAREXEL’s early phase services provide fully integrated solutions from First in Man through Proof of Concept and help biopharmaceutical companies generate better and faster go/no-go decisions about their compounds, and strive to return solid, reproducible outcomes to succeed in later-phase trials. PAREXEL’s early phase capabilities include a full scope of early phase studies, specialized trial design, state-of-the-art technologies, hospital-based resources, and scientific expertise as well as vast experience in the oncology, neurology, cardiology, respiratory, and metabolism/endocrine therapeutic areas. For more information about PAREXEL’s early phase capabilities visit: http://www.PAREXEL.com/Early_Phase.html.
PAREXEL International Corporation is a leading global biopharmaceutical services organization, providing a broad range of knowledge-based contract research, medical communications and consulting services to the worldwide pharmaceutical, biotechnology and medical device industries. Committed to providing solutions that expedite time-to-market and peak-market penetration, PAREXEL has developed significant expertise across the development and commercialization continuum, from drug development and regulatory consulting to clinical pharmacology, clinical trials management, medical education and reimbursement. Perceptive Informatics, Inc., a subsidiary of PAREXEL, provides advanced technology solutions, including medical imaging, to facilitate the clinical development process. Headquartered near Boston, Massachusetts, PAREXEL operates in 71 locations throughout 50 countries around the world, and has approximately 9,200 employees. For more information about PAREXEL International visit www.PAREXEL.com.
PAREXEL is a registered trademark of PAREXEL International Corporation, and Perceptive Informatics is a trademark of Perceptive Informatics, Inc. All other names or marks may be registered trademarks or trademarks of PAREXEL International Corporation, Perceptive Informatics, Inc. or their respective owners and are hereby acknowledged.
CONTACT: Jennifer Baird, Senior Director of Public Relations, PAREXEL
International, +1-781-434-4409, Jennifer.Baird@PAREXEL.com; Gene Carozza or
Kim Baker, both of PAN Communications, +1-978-474-1900, PAREXEL@pancomm.com
Web site: http://www.parexel.com/